- Home
- BZUN vs INZY Comparison
BZUN vs INZY Comparison
Compare BZUN & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- INZY
- Stock Information
- Founded
- BZUN 2007
- INZY 2015
- Country
- BZUN China
- INZY United States
- Employees
- BZUN N/A
- INZY N/A
- Industry
- BZUN Catalog/Specialty Distribution
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- BZUN Consumer Discretionary
- INZY Health Care
- Exchange
- BZUN Nasdaq
- INZY Nasdaq
- Market Cap
- BZUN 188.7M
- INZY 188.2M
- IPO Year
- BZUN N/A
- INZY 2020
- Fundamental
- Price
- BZUN $3.25
- INZY $1.36
- Analyst Decision
- BZUN Strong Buy
- INZY Strong Buy
- Analyst Count
- BZUN 3
- INZY 8
- Target Price
- BZUN $3.20
- INZY $17.75
- AVG Volume (30 Days)
- BZUN 427.0K
- INZY 1.0M
- Earning Date
- BZUN 03-20-2025
- INZY 03-11-2025
- Dividend Yield
- BZUN N/A
- INZY N/A
- EPS Growth
- BZUN N/A
- INZY N/A
- EPS
- BZUN N/A
- INZY N/A
- Revenue
- BZUN $1,312,737,613.00
- INZY N/A
- Revenue This Year
- BZUN $8.16
- INZY N/A
- Revenue Next Year
- BZUN $4.71
- INZY N/A
- P/E Ratio
- BZUN N/A
- INZY N/A
- Revenue Growth
- BZUN 7.26
- INZY N/A
- 52 Week Low
- BZUN $2.11
- INZY $1.24
- 52 Week High
- BZUN $4.38
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- BZUN 58.19
- INZY 29.28
- Support Level
- BZUN $3.05
- INZY $1.35
- Resistance Level
- BZUN $3.43
- INZY $1.62
- Average True Range (ATR)
- BZUN 0.17
- INZY 0.13
- MACD
- BZUN 0.03
- INZY 0.04
- Stochastic Oscillator
- BZUN 74.26
- INZY 32.89
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.